By Siddhi Mahatole March 24 (Reuters) - Shares of ImmunityBio fell 26% on Tuesday after the U.S. Food and Drug Administration ...
Stocktwits on MSN
IBRX stock still a buy after worst day in over a year? Why this analyst is shrugging off FDA warning letter
BTIG maintained its 'Buy' rating and $13 price target, implying about 75% upside, and said the warning relates to promotion ...
ImmunityBio Inc.’s shares plunged after the biotechnology company and its billionaire Executive Chairman Patrick Soon-Shiong ...
Simtra BioPharma Solutions was issued a warning letter by the FDA after an inspection uncovered a number of problems at the ...
Testing identified significant impurity formation when tirzepatide is compounded with B12 variants, suggesting chemical incompatibility that is not evaluated under FDA review pathways. Uncertainty ...
Novo Nordisk issued a response to an FDA warning letter that cited serious violations in how the company tracked and reported ...
Pharmaceutical Technology on MSN
FDA issues warning to Novo Nordisk on unreported semaglutide safety events
In the warning letter, the FDA alleged that Novo inadequately responded to observations made after an inspection carried out ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive ...
Intas Pharmaceuticals’ new warning letter from the U.S. FDA reads like a checklist of what not to do when the regulator pays a visit to your manufacturing facility. The FDA handed Intas a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results